[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560242":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":32,"locations":37,"responsibleParty":50,"collaborators":17,"id":54,"slug":17,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":17,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":17,"enrollmentInfo":62,"targetDuration":17,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":39,"whyStopped":17,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Konkuk University Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"MTX discontinuation","EXPERIMENTAL","methotrexate stop for 2 weeks after each shingrix vaccination",[13],"Drug: Methotrexate",{"label":15,"type":16,"description":17,"interventionNames":18},"MTX continuation","ACTIVE_COMPARATOR",null,[13],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":17},"DRUG","Methotrexate","methotrexate discontinuation group : stop MTX for 2 weeks after each shingrix vaccination",[9],{"type":21,"name":22,"description":26,"armGroupLabels":27,"otherNames":17},"methotrexate continuation group : keep methotrexate",[15],[29],{"name":30,"affiliation":5,"role":31},"Hong Ki Min, MD, PhD","STUDY_CHAIR",[33],{"name":30,"role":34,"phone":35,"phoneExt":17,"email":36},"CONTACT","+82-10-9977-5455","alsghdrl1921@naver.com",[38],{"facility":5,"status":39,"city":40,"state":17,"zip":17,"country":41,"countryCode":17,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Seoul","South Korea",{"type":43,"coordinates":44},"Point",[45,46],126.9784,37.566,{"lat":46,"lon":45},[49],{"name":30,"role":34,"phone":35,"phoneExt":17,"email":36},{"type":51,"investigatorFullName":52,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Hong Ki Min","Assistant Professor","100560242",false,"NCT06574594","Effect of MTX Discontinuation on Shingrix Response in RA","Effect of Methotrexate Discontinuation on Immunogenicity of Shingrix in Patients With Rheumatoid Arthritis","Inclusion Criteria:\n\n* fulfill 2010 ACR\u002FEULAR classification criteria for rheumatoid arthritis\n* age over 19 years\n* methotrexate user\n* agree for vaccination with shingrix\n\nExclusion Criteria:\n\n* have other form of inflammatory arthritis or autoimmune-mediated disease\n* malignancy, current infection, pregnancy","ALL","19 Years",{"count":63,"type":64},110,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to learn if methotrexate discontinuation affect on immunogeneity of shingrix in RA patients. The main questions it aims to answer are:\n\nDiscontinuation of methotrexate after shingrix immunization increase efficacy of the vaccine in patients with RA ?\n\nResearchers will compare humoral and cell-mediated immunity against herpes zoster in RA patients who are vaccinated by shingrix, and compare these immunity between RA patients with MTX discontinuation and MTX continuation groups.\n\nParticipants will:\n\nVaccinated with shingrix twice. MTX continuation group will keep taking MTX after shingrix vaccination, whereas MTX discontinuation group will stop MTX for 2 weeks after shingrix vaccination.\n\nVisit the clinic at baseline (first shingrix vaccination), 2 months later for 2nd shingrix vaccination, then 3 \\& 6 months later from baseline to achieve blood sample.",[70],"Rheumatoid Arthritis",[72,73,74],"herpes zoster","Shingrix","methotrexate","2024-08-25",{"date":77,"type":78},"2024-08-28","ACTUAL",{"date":80,"type":64},"2024-08-22",{"date":82,"type":64},"2025-12-31",{"name":5,"class":6},1]